Competitive inroads by Regeneron’s Eylea in the retinal vein occlusion treatment landscape changed the market once dominated by Roche.Moving forward, RVO’s robust pipeline, along with several VEGF inhibitors, creates trouble for the big ones; Lucentis and Eylea.
Retinal vein occlusion is the second most common sight-threatening retinal vascular disorder following diabetic retinopathy and the common cause of vision loss in older individuals. As per our estimates, there were approximately 1.5 million diagnosed prevalent cases of retinal vein occlusion in the 7MM in 2021, which is further expected to increase by 2032. Moreover, In the 7MM, total gender-specific diagno...
